BRISBANE, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) announced today that it will report financial results for the third quarter ended September 30, 2016 after market close on Thursday, October 27, 2016. Innoviva management will host a webcast and conference call at 5:00 p.m. EDT that day to discuss the financial results and provide a corporate update.
To participate in the live call dial (877) 837-3908 from the U.S., or (973) 890-8166 for international callers and enter Conference ID: 97037854. A live webcast of the call will be available at: http://edge.media-server.com/m/p/6stsppn8 or from the investor relations section of the company website at www.inva.com and will be archived for 30 days. A telephone replay of the call will be available through Nov. 3, 2016, by dialing (855) 859-2056 from the U.S., or (404) 537-3406 for international callers and entering Conference ID: 97037854.
Innoviva is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. Innoviva's portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, which were jointly developed by Innoviva and GSK. Under the agreement with GSK, Innoviva is eligible to receive associated royalty revenues from RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and, if approved and commercialized, VI monotherapy, as well. In addition, Innoviva retains a 15 percent economic interest in future payments made by GSK for earlier-stage programs partnered with Theravance Biopharma, Inc. For more information, please visit Innoviva's website at www.inva.com.
ANORO®, RELVAR®, BREO® and ELLIPTA® are trademarks of the GlaxoSmithKline group of companies.